Concord Drugs Ltd
Concord Drugs Ltd (CONCORD) last traded at ₹78.4, a market capitalisation of ₹103 crore, on a P/E of 50.4. Over the past 52 weeks the stock has ranged between ₹56 and ₹92.5. Concord Drugs Ltd last reported results for the quarter ended Jun 2026, with sales of ₹20.95 crore and net profit of ₹1.11 crore. Figures are as of 25 Aug 2026 and are not real time.
Concord Drugs Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Concord Drugs Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹20.95 cr, up 53.9% from ₹13.61 cr a year earlier. Net profit was ₹1.11 cr, up 825.0% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 12.37 | 10.8 | 10.39 | 13.61 | 10.28 | 16.99 | 37.9 | 20.95 |
| Expenses | 11.49 | 9.4 | 9.34 | 12.59 | 9.18 | 16.05 | 36.4 | 18.66 |
| Operating profit | 0.88 | 1.4 | 1.05 | 1.02 | 1.1 | 0.94 | 1.5 | 2.29 |
| OPM % | 7.11% | 12.96% | 10.11% | 7.49% | 10.70% | 5.53% | 3.96% | 10.93% |
| Other income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0.47 | 0.5 | 0.61 | 0.49 | 0.49 | 0.34 | 0.4 | 0.4 |
| Depreciation | 0.34 | 0.37 | 0.38 | 0.37 | 0.34 | 0.31 | 0.35 | 0.35 |
| Profit before tax | 0.07 | 0.53 | 0.06 | 0.16 | 0.27 | 0.29 | 0.75 | 1.54 |
| Tax % | 42.86% | 58.49% | 33.33% | 25.00% | 29.63% | 27.59% | 29.33% | 27.92% |
| Net profit | 0.04 | 0.23 | 0.04 | 0.12 | 0.19 | 0.22 | 0.53 | 1.11 |
| EPS (₹) | 0.04 | 0.23 | 0.04 | 0.12 | 0.19 | 0.17 | 0.40 | 0.84 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Concord Drugs Ltd annual results
| ₹ crore | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|
| Sales | 58.96 | 52.08 | 44.92 | 45.24 | 78.77 | 86.12 |
| Operating profit | 5.59 | 4.57 | 4.04 | 4.14 | 4.55 | 5.83 |
| OPM % | 9.48% | 8.77% | 8.99% | 9.15% | 5.78% | 6.77% |
| Net profit | 1.59 | 0.99 | 0.47 | 0.34 | 1.06 | 2.05 |
| EPS (₹) | 1.82 | 1.06 | 0.47 | 0.34 | 0.80 | 1.60 |
TTM is the trailing twelve months to the most recent quarter.
Concord Drugs Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 15%
- TTM
- 83%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 2%
- TTM
- 377%
- 10 Years
- 3%
- 5 Years
- 24%
- 3 Years
- 29%
- 1 Year
- 43%
- 10 Years
- %
- 5 Years
- 3%
- 3 Years
- 2%
- Last Year
- 3%
Concord Drugs Ltd shareholding pattern
Promoters held 45.08% at Jun 2026, down from 54.39% at Jun 2025.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 54.39% | 54.39% | 54.39% | 54.39% | 54.39% | 54.39% | 54.39% | 45.08% |
| Public | 45.61% | 45.61% | 45.61% | 45.61% | 45.61% | 45.61% | 45.61% | 54.92% |
| No. of shareholders | 5,073 | 5,073 | 5,252 | 5,189 | 4,718 | 4,597 | 4,464 | 4,435 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Concord Drugs Ltd corporate filings
- Copy of News-paper publications for quarterly results ended 30th June 2026.Company Updatehigh impact
Cruxal's analysis: Concord Drugs Limited has released its unaudited financial results for the quarter ended…
Read the full analysis - Outcome of Board meetingBoard Meetinghigh impact
Cruxal's analysis: Concord Drugs Limited reported a robust performance for the quarter ended 30 June 2026…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Concord Drugs Ltd
Cruxal reads every Concord Drugs Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.